This study compares two treatments, Pumitamig and Pembrolizumab, for people with advanced Non-Small Cell Lung Cancer (NSCLC), which is a type of lung cancer that's spread beyond the lungs. Participants need to have high levels (≥ 50%) of a protein called PD-L1, which helps cancer cells hide from the immune system. To join, participants must have NSCLC confirmed by medical tests, no previous cancer treatments, and be in good health to participate (ECOG status 0-1, meaning fully active or restricted in physically strenuous activity but able to carry out light work).

Key Points:

• The study compares two cancer treatments to see which is better.
• Participants must have advanced lung cancer with specific conditions.
• It's important to ensure participants meet all eligibility criteria.

Participants can't join if they have other major health issues like severe heart problems, untreated brain issues, or active autoimmune diseases. The study will check if the treatments help and what side effects they might have. It's important to talk with your doctor to see if joining this study is a good choice for you.